203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v

Tweet Author

Tweet Content

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://t.co/zSxt0W9ZhB https://t.co/k9rCUSel3e

Links

https://bit.ly/3lYb8S7

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Res

Tweet Author

RheumNow

Tweet Content

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

Links

https://bit.ly/3zhrpVl

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing author

Tweet Author

RheumNow

Tweet Content

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Links

https://bit.ly/40thmIM

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat th

Tweet Author

RheumNow

Tweet Content

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/mqmQ7jzbpj https://t.co/9FrIOAYJwA

Links

https://bit.ly/3nARvQw

Intrathecal Methotrexate for Cerebritis (3.31.2023)

31 March 2023

Intrathecal Methotrexate for Cerebritis (3.31.2023)

Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=4) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https://bit.ly/3lOlWlT

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SL

Tweet Author

RheumNow

Tweet Content

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/1ZiRX3jUGV https://t.co/k0a54QJ9Hi

Links

https://bit.ly/3G9lVzF

30 March 2023

Alcohol Differences in Urate Level Elevation

Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.

A cross-sectional study of Japanese adults (over age 20 yrs) examined effects of different alcohol types on lab results. Analyses were standardized the unit of intake for ethanol content. Specifically they looked at the effects of beer, sake (rice wine), shochu (Japanese spirit), wine, and whiskey.

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for th

Tweet Author

RheumNow

Tweet Content

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/kX3dg9DGuw https://t.co/b27CX6Bn0h

Links

https://bit.ly/3G44JeY

LAVLI - A New Autoinflammatory DisorderNIH researchers have have described a novel autoinflammatory disorder called "L

Tweet Author

RheumNow

Tweet Content

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/VWs0YuF4LD https://t.co/7ydA3bb82j

Links

https://bit.ly/3FZ7z4H

Topics

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Res

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing author

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat th

Intrathecal Methotrexate for Cerebritis (3.31.2023)

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SL

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for th

LAVLI - A New Autoinflammatory DisorderNIH researchers have have described a novel autoinflammatory disorder called "L

Do you get our email newsletter?

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I &amp; II trials show Week 16 50% HS Res

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing author

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat th

Intrathecal Methotrexate for Cerebritis (3.31.2023)

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SL

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for th

LAVLI - A New Autoinflammatory DisorderNIH researchers have have described a novel autoinflammatory disorder called "L

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Res